SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)

• M. Lázaro ^[5] ; E. Gallardo ^[6] ; M. Doménech ^[7] ; Á. Pinto ^[1] ; A. González del Alba ^[2] ; J. Puente ^[8] ; O. Fernández ^[9] ; A. Font ^[10] ; N. Lainez ^[3] ; S. Vázquez ^[4]
  1. [1] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  2. [2] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  3. [3] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
  4. [4] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  5. [5] Hospital Álvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo, España
  6. [6] Parc Taulí Sabadell Hospital Universitari, España
  7. [7] Xarxa Assisencial i Universitària de Manresa, España
  8. [8] Hospital Universitario San Carlos, España
  9. [9] Complexo Hospitalario Universitario de Ourense, España
  10. [10] Hospital Universitario Germans Trias i Pujol, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1197-1205
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice. In muscle-invasive bladder cancer, neoadjuvant chemotherapy should be recommended in patients with good performance status and no renal function impairment. Although there is insufficient evidence for use of adjuvant chemotherapy, its use must be considered when neoadjuvant therapy had not been administered in high-risk patients. Multimodality bladder-preserving treatment in localized disease is an alternative in selected and compliant patients for whom cystectomy is not considered for clinical or personal reasons. In metastatic disease, the first-line treatment for patients must be based on cisplatin-containing combination. Vinflunine is the only drug approved for use in second line in Europe. Recently, immunotherapy treatment has demonstrated activity in this setting.